Mostrando 2 resultados de: 2
Phase i/ii clinical trial of the humanized anti-egf-r monoclonal antibody h-r3 labelled with <sup>99m</sup>tc in patients with tumour of epithelial origin
ArticleAbstract: To evaluate the biodistribution, internal radiation dosimetry and toxicity of the humanized MAb h-R3Palabras claves:biodistribution, Dosimetry, Humanized MAb, RadioimmunodiagnosisAutores:Aguilar V., Batista J.F., Coca M.A., Hernández A., Iznaga-Escobar N., Neninger Vinageras E., Perera A., Pérez M., Ramos M., Romero S., Sánchez E., Tania Crombet, Torres L.Fuentes:scopusUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
ArticleAbstract: Purpose: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor rPalabras claves:Autores:Alvarez D., Cruz T., Del Castillo R., Fernández E., Figueredo R., Iznaga-Escobar N., Koropatnick J., Lage Davila A., Leonard I., Mon R., Osorio M., Pérez R., Ramos M., Renginfo E., Roca C., Tania Crombet, Torres O.Fuentes:scopus